Aldose Reductase Inhibitor Ameliorates Renal Vascular Endothelial Growth Factor Expression in Streptozotocin-Induced Diabetic Rats

키워드

참고문헌 (32)

1. Derubertis FR, "Activation of protein kinase C in glomerular cells in diabetes. Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy", Diabetes, 43, pp.1~8 (1994)
2. Yamagishi S, "Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells", J Biol Chem, 227, pp.20309~20315 (2002)
3. Natarajan R, "Effects of high glucose on vascular endothelial growth factor expression in vascular smooth muscle cells", Am J Physiol, 273, pp.H2224~2231 (1997)
4. Keogh RJ, "Effect of inhibition of aldose reductase on glucose flux, diacylglycerol formation, protein kinase C, and phospholipase A2 activation", Metabolism, 46, pp.41~47 (1997)
5. Kim NH, "Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells", J Endocrinol, 165, pp.617~624 (2000)
6. Tsuchida K, "Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195", Diabetologia, 42, pp.579~588 (1999)
7. Lu M, "Advanced glycation end products increase retinal vascular endothelial growth factor expression", J Clin Invest, 101, pp.1219~1224 (1998)
8. Wang L, "Transforming growth factor-beta1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells", J Biol Chem, 279, pp.33213~33219 (2004)
9. Kuroki M, "Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo", J Clin Invest, 98, pp.1667~1675 (1996)
10. Ferrara N, "Role of vascular endothelial growth factor in the regulation of angiogenesis", Kidney Int, 56, pp.794~814 (1999)
11. Cha DR, "Urinary concentration of transforming growth factor-beta-inducible gene-h3(beta ig-h3) in patients with Type 2 diabetes mellitus", Diabet Med, 22, pp.14~20 (2005)
12. Cooper ME, "Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes", Diabetes, 48, pp.2229~2239 (1999)
13. de Vriese AS, "Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes", J Am Soc Nephrol, 12, pp.993~1000 (2001)
14. 이은영, "Angiotensin II receptor blocker attenuates overexpression of vascular endothelial growth factor in diabetic podocytes", Experimental and Molecular Medicine, 36(1), pp.65~70 (2004), 생화학분자생물학회
15. Fonseca VA, "Clinical diabetes: translating research into practice" (2006), Saunders Elsevier
16. Tilton RG, "Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor", J Clin Invest, 99, pp.2192~2202 (1997)
17. Obrosova IG, "Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats", Diabetes, 52, pp.864~871 (2003)
18. Lane PH, "Estimation of glomerular volume: a comparison of four methods", Kidney Int, 41, pp.1085~1089 (1992)
19. Saito T, "The enhancement of aminonucleoside nephrosis by the co-administration of protamine", Kidney Int, 32, pp.691~699 (1987)
20. Ziyadeh FN, "The extracelluar matrix in diabetic nephropathy", Am J Kidney Dis, 22, pp.736~744 (1993)
21. Craven PA, "Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose", J Clin Invest, 83, pp.1667~1675 (1989)
22. Ghahary A, "Increased renal aldose reductase activity, immunoreactivity, and mRNA in streptozocin-induced diabetic rats", Diabetes, 38, pp.1067~1071 (1989)
23. Raptis AE, "Pathogenesis of diabetic nephropathy", Exp Clin Endocrinol Diabetes, 109, pp.S424~437 (2001)
24. Donnelly SM, "Prevention of early glomerulopathy with tolrestat in the streptozotocin-induced diabetic rat", Biochem Cell Biol, 74, pp.355~362 (1996)
25. Isogai S, "Effect of an aldose reductase inhibitor on glomerular basement membrane anionic sites in streptozotocin-induced diabetic rats", Diabetes Res Clin Pract, 30, pp.111~116 (1995)
26. Obrosova IG, "How dose glucose generate oxidative stress in peripheral nerve?", Int Rev of Neurobiol, 50, pp.3~35 (2002)
27. Lee AY, "Contributions of polyol pathway to oxidative stress in diabetic cataract", FASEB J, 13, pp.23~30 (1999)
28. Obrosova IG, "An aldose reductase inhibitor reverse early diabetesinduced changes in peripheral nerve function, metabolism, and antioxidative defense", FASEB J, 16, pp.123~125 (2002)
29. Kuroki M, "Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and vivo", J Clin Invest, 98, pp.1667~1675 (1996)
30. Hoshi S, "Podocyte injury promotes progressive nephropathy in zucker diabetic fatty rats", Lab Invest, 82, pp.25~35 (2002)
31. Foppiano M, "Worldwide pharmacovigilance system and tolrestat withdrawal", Lancet, 349, pp.399~400 (1997)
32. Otani A, "Angiotensin II potentiates vascular endothelial growth factor-induced angiogenetic activity in retinal microcapillary endothelial cells", Circ Res, 82, pp.619~628 (1998)

관련 논문AI추천